Background Myocarditis is a highly morbid complication of immune checkpoint inhibitor (ICI)
use that remains inadequately characterized. The QRS duration and the QTc interval are …

The innovative development of cancer therapies has led to an unprecedented improvement
in survival outcomes and a wide array of treatment-related toxicities, including those that are …

Cardiotoxicity is a well-established complication of multiple cancer therapeutics, and the one
of the most prominent effects that limits the use of these agents is in the form of left …

Chimeric antigen receptor (CAR)-T cell therapy is effective in the treatment of
refractory/relapsed (r/r) hematological malignancies (r/r B-cell lymphoblastic leukemia, B-cell …

Introduction As chimeric antigen receptor T-cell therapies are becoming increasingly
available in the armamentarium of the hematologist, there is an emerging need to monitor …

Oncology has seen growing use of newly developed targeted therapies. Although this has
resulted in dramatic improvements in progression-free and overall survival, challenges in …

Chimeric antigen receptor (CAR) T cell therapy is approved in the United States for the
treatment of acute lymphocytic leukemia and aggressive B cell lymphomas. Multiple …

Purpose of review Contemporary anticancer immunotherapy, particularly immune
checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell therapy, has changed …

Cancer is one of the leading causes of morbidity and mortality worldwide. Significant
improvements in the modern era of anticancer therapeutic strategies have increased the …

The evolution of cancer treatment and development of new classes of anticancer therapies
have continued to revolutionize the field of oncology. New therapies including targeted …